The Potency Problem in GPCR Biased Agonism
ACS Chemical Neuroscience · 27.10.2026
DOI: 10.1021/acschemneuro.6c00783 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, online erschienen am 27.10.2026. Verfasst von Cassandra J. Hatzipantelis. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Biased agonism promised a new generation of GPCR therapeutics capable of selectively engaging beneficial signaling pathways while avoiding those associated with adverse effects. Yet contemporary bias metrics largely quantify signaling efficiency through potency-centric measures, emphasizing pathway preference over the pathway exclusion that may better align with the original promise of biased agonism. I argue that efficacy-centered descriptors, including a simple complementary E-factor (ΔΔlog(EMax)), may help identify ligands with therapeutically relevant functional selectivity and should be reported alongside conventional bias factors to provide a more complete assessment of biased signaling.
Zitieren
APA
Hatzipantelis, C. J. (2026). The Potency Problem in GPCR Biased Agonism. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.6c00783
Vancouver
Hatzipantelis CJ. The Potency Problem in GPCR Biased Agonism. ACS Chemical Neuroscience. 2026. doi:10.1021/acschemneuro.6c00783
BibTeX
@article{Hatzipantelis2026,
author = {Hatzipantelis, Cassandra J.},
title = {The Potency Problem in GPCR Biased Agonism},
journal = {ACS Chemical Neuroscience},
year = {2026},
doi = {10.1021/acschemneuro.6c00783}
}
EUVIMED